Challenges in implementing and maintaining osteoporosis therapy

References

• Dawson-HughesBLookerACTostesonANJohanssonHKanisJAMeltonLJThe potential impact of the National Osteoporosis Foundation guidance on treatment eligibility in the USA: an update in NHANES 2005–2008Osteoporos Int201223381182021717247
   PubMed Web of Science ®Google Scholar
• BurgeRDawson-HughesBSolomonDHWongJBKingATostesonAIncidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025J Bone Miner Res200722346547517144789
   PubMed Web of Science ®Google Scholar
• CooperCColeZAHolroydCRIOF CSA Working Group on Fracture EpidemiologySecular trends in the incidence of hip and other osteoporotic fracturesOsteoporos Int20112251277128821461721
   PubMed Web of Science ®Google Scholar
• JohnellOKanisJAAn estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporos Int200617121726173316983459
   PubMed Web of Science ®Google Scholar
• KanisJAJohnellORequirements for DXA for the management of osteoporosis in EuropeOsteoporos Int200516322923815618996
   PubMed Web of Science ®Google Scholar
• AdachiJDAdamiSGehlbachSGLOW InvestigatorsImpact of prevalent fractures on quality of life: baseline results from the global longitudinal study of osteoporosis in womenMayo Clin Proc201085980681320634496
   PubMed Web of Science ®Google Scholar
• SaleJEBeatonDPosenJElliot-GibsonVBogochESystematic review on interventions to improve osteoporosis investigation and treatment in fragility fracture patientsOsteoporos Int20112272067208221607808
   PubMed Web of Science ®Google Scholar
• ShepherdAJCassARRayLATanAWilkinsonGSTreatment for older men with fracturesOsteoporos Int20122331041105121811867
   PubMed Web of Science ®Google Scholar
• DelmasPDvan de LangerijtLWattsNBIMPACT Study GroupUnderdiagnosis of vertebral fractures is a worldwide problem: the IMPACT studyJ Bone Miner Res200520455756315765173
   PubMed Web of Science ®Google Scholar
• Shibli-RahhalAVaughan-SarrazinMSRichardsonKCramPTesting and treatment for osteoporosis following hip fracture in an integrated US. healthcare delivery systemOsteoporos Int201122122973298021271339
   PubMed Web of Science ®Google Scholar
• LeslieWDGiangregorioLMYogendranMA population-based analysis of the post-fracture care gap 1996–2008: the situation is not improvingOsteoporos Int20122351623162921476038
   PubMed Web of Science ®Google Scholar
• FeldsteinACNicholsGAElmerPJSmithDHAickinMHersonMOlder women with fractures: patients falling through the cracks of guideline-recommended osteoporosis screening and treatmentJ Bone Joint Surg Am200385-A122294230214668497
   PubMed Web of Science ®Google Scholar
• JohnellKFastbomJUndertreatment of osteoporosis in the oldest old? A nationwide study of over 700,000 older peopleArch Osteoporos200941–2172320234854
   PubMedGoogle Scholar
• KiebzakGMBeinartGAPerserKAmbroseCGSiffSJHeggenessMHUndertreatment of osteoporosis in men with hip fractureArch Intern Med2002162192217222212390065
   PubMedGoogle Scholar
• MajumdarSRLixLMYogendranMMorinSNMetgeCJLeslieWDPopulation-based trends in osteoporosis management after new initiations of long-term systemic glucocorticoids (1998–2008)J Clin Endocrinol Metab20129741236124222298803
   PubMed Web of Science ®Google Scholar
• McKeownEBykerkVPDe LeonFCATCH InvestigatorsQuality assurance study of the use of preventative therapies in glucocorticoid-induced osteoporosis in early inflammatory arthritis: results from the CATCH cohortRheumatology (Oxford)20125191662166922539481
   PubMed Web of Science ®Google Scholar
• KanisJAMcCloskeyEVJohanssonHCooperCRizzoliRReginsterJYScientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF)European guidance for the diagnosis and management of osteoporosis in postmenopausal womenOsteoporos Int2013241235723079689
   PubMed Web of Science ®Google Scholar
• National Osteoporosis Foundation2013 Clinician’s Guide to the Prevention and Treatment of OsteoporosisWashington, DCNational Osteoporosis Foundation2013 Available from: http://nof.org/hcp/resources/913Accessed May 24, 2013
   Google Scholar
• nice.org.uk [homepage on the Internet]Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women [NICE technology appraisal guidance TA161]NHS National Institute for Health and Clinical Excellence (NICE)2011 [updated August 27, 2013; cited May 24, 2013]. Available from: http://guidance.nice.org.uk/TA161Accessed October 24, 2013
   Google Scholar
• NHS National Institute for Health and Clinical Excellence (NICE)Alendronate, Etidronate, Risedronate, Raloxifene and Strontium Ranelate for the Primary Prevention of Osteoporotic Fragility Fractures in Postmenopausal Women (Amended). NICE Technology Appraisal Guidance 160 (Amended)LondonNational Institute for Health and Clinical Excellence2011 Available from: http://www.nice.org.uk/nicemedia/live/11746/47176/47176.pdfAccessed May 24, 2013
   Google Scholar
• PapaioannouAMorinSCheungAMScientific Advisory Council of Osteoporosis Canada2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summaryCMAJ2010182171864187320940232
   PubMed Web of Science ®Google Scholar
• iofbonehealth.org [homepage on the Internet]National and regional osteoporosis guidelinesInternational Osteoporosis Foundation2013 [cited May 24, 2013]. Available from: http://www.iofbonehealth.org/national-regional-osteoporosis-guidelinesAccessed October 24, 2013
   Google Scholar
• health.ny.gov [homepage on the Internet]FDA-approved medications for osteoporosis treatmentNew York State Osteoporosis Prevention and Education Program2012 [updated Jun 2012, cited May 24, 2013]. Available from: http://www.health.ny.gov/diseases/conditions/osteoporosis/fda_meds_and_prevention.htmAccessed October 24, 2013
   Google Scholar
• nof.gov [homepage on the Internet]Types of osteoporosis medicationsNational Osteoporosis Foundation2013 [cited May 24, 2013]. Available from: http://www.nof.org/articles/22Accessed October 24, 2013
   Google Scholar
• shef.ac.uk [homepage on the Internet]FRAX^® WHO Fracture Risk Assessment ToolWorld Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield2013 [cited May 24, 2013]. Available from: http://www.shef.ac.uk/FRAX/Accessed October 24, 2013
   Google Scholar
• KanisJAWorld Health Organization Scientific GroupAssessment of Osteoporosis at the Primary Health Care Level. Technical ReportSheffieldWorld Health Organization Collaborating Centre for Metabolic Bone Diseases, University of Sheffield2007
   Google Scholar
• KanisJAOdénAMcCloskeyEVJohanssonHWahlDACooperCIOF Working Group on Epidemiology and Quality of LifeA systematic review of hip fracture incidence and probability of fracture worldwideOsteoporos Int20122392239225622419370
   PubMed Web of Science ®Google Scholar
• LewieckiEMCompstonJEMillerPDFRAX® Position Development Conference MembersOfficial positions for FRAX® bone mineral density and FRAX® simplification from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®J Clin Densitom201114322623621810530
   PubMed Web of Science ®Google Scholar
• CanalisEMazziottiGGiustinaABilezikianJPGlucocorticoid-induced osteoporosis: pathophysiology and therapyOsteoporos Int200718101319132817566815
   PubMed Web of Science ®Google Scholar
• WeinsteinRSClinical practice. Glucocorticoid-induced bone diseaseN Engl J Med20113651627021732837
   PubMed Web of Science ®Google Scholar
• GrossmanJMGordonRRanganathVKAmerican College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosisArthritis Care Res (Hoboken)201062111515152620662044
   PubMed Web of Science ®Google Scholar
• Bone and Tooth Society, National Osteoporosis Society, Royal College of PhysiciansGlucocorticoid-induced osteoporosis: guidelines for prevention and treatmentLondon: LondonRoyal College of Physicians2002
   Google Scholar
• DevogelaerJPGoemaereSBoonenSEvidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone ClubOsteoporos Int200617181916217586
   PubMed Web of Science ®Google Scholar
• AdachiJDSaagKGDelmasPDTwo-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trialArthritis Rheum200144120221111212161
   PubMed Web of Science ®Google Scholar
• VestergaardPSchwartzKPinholtEMRejnmarkLMosekildeLGastric and esophagus events before and during treatment of osteoporosisCalcif Tissue Int201086211011519957165
   PubMed Web of Science ®Google Scholar
• EnsrudKELuiLYTaylorBCOsteoporotic Fractures Research GroupRenal function and risk of hip and vertebral fractures in older womenArch Intern Med2007167213313917242313
   PubMedGoogle Scholar
• NickolasTLMcMahonDJShaneERelationship between moderate to severe kidney disease and hip fracture in the United StatesJ Am Soc Nephrol200617113223323217005938
   PubMed Web of Science ®Google Scholar
• JamalSAWestSLMillerPDFracture risk assessment in patients with chronic kidney diseaseOsteoporos Int20122341191119821901475
   PubMed Web of Science ®Google Scholar
• CocoMRushHIncreased incidence of hip fractures in dialysis patients with low serum parathyroid hormoneAm J Kidney Dis20003661115112111096034
   PubMed Web of Science ®Google Scholar
• Kidney disease: Improving Global Outcomes (KDIGO) CKD-MBD Work GroupKDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)Kidney Int Suppl2009113S1S130
   Google Scholar
• MoeSDrüekeTCunninghamJKidney Disease: Improving Global Outcomes (KDIGO)Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO)Kidney Int200669111945195316641930
   PubMed Web of Science ®Google Scholar
• MillerPDThe kidney and bisphosphonatesBone2011491778121232648
   PubMed Web of Science ®Google Scholar
• fda.gov [homepage on the Internet]FDA drug safety communication: New contraindication and updated warning on kidney impairment for Reclast (zoledronic acid)US Food and Drug Administration (FDA)2011 [updated September 20, 2011, cited October 10, 2013]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htmAccessed October 10, 2013
   Google Scholar
• Fosamax^®(alendronate sodium) [package insert]Whitehouse Station, NJMerck and Co, Inc2012
   Google Scholar
• Actonel^® (risedronate sodium) [package insert]Norwich Pharmaceuticals, IncNorth Norwich, NY2012
   Google Scholar
• Boniva^® (ibandronate sodium) [package insert]San Francisco, CAGenentech, Inc2011
   Google Scholar
• UhligKBernsJSKestenbaumBKDOQI US commentary on the 2009 KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of CKD-Mineral and Bone Disorder (CKD-MBD)Am J Kidney Dis201055577379920363541
   PubMed Web of Science ®Google Scholar
• MillerPDFragility fractures in chronic kidney disease: an opinion-based approachCleve Clin J Med2009761271572319952296
   PubMed Web of Science ®Google Scholar
• DonaldsonMGCawthonPMLuiLYOsteoporotic Fractures in Men (MrOS) Study GroupEstimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelinesJ Bone Miner Res20102571506151120200971
   PubMed Web of Science ®Google Scholar
• KanisJABianchiGBilezikianJPTowards a diagnostic and therapeutic consensus in male osteoporosisOsteoporos Int201122112789279821509585
   PubMed Web of Science ®Google Scholar
• GatesBJDasSManagement of osteoporosis in elderly menMaturitas201169211311921481552
   PubMed Web of Science ®Google Scholar
• MacLeanCNewberrySMaglioneMSystematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosisAnn Intern Med2008148319721318087050
   PubMed Web of Science ®Google Scholar
• LiuHPaigeNMGoldzweigCLScreening for osteoporosis in men: a systematic review for an American College of Physicians guidelineAnn Intern Med2008148968570118458282
   PubMed Web of Science ®Google Scholar
• EbelingPRClinical practice. Osteoporosis in menN Engl J Med2008358141474148218385499
   PubMed Web of Science ®Google Scholar
• CenterJRBliucDNguyenTVEismanJARisk of subsequent fracture after low-trauma fracture in men and womenJAMA2007297438739417244835
   PubMed Web of Science ®Google Scholar
• BliucDNguyenNDMilchVENguyenTVEismanJACenterJRMortality risk associated with low-trauma osteoporotic fracture and subsequent fracture in men and womenJAMA2009301551352119190316
   PubMed Web of Science ®Google Scholar
• KannegaardPNvan der MarkSEikenPAbrahamsenBExcess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survivalAge Ageing201039220320920075035
   PubMed Web of Science ®Google Scholar
• WehrenLEHawkesWGOrwigDLHebelJRZimmermanSIMagazinerJGender differences in mortality after hip fracture: the role of infectionJ Bone Miner Res200318122231223714672359
   PubMed Web of Science ®Google Scholar
• CawthonPMEwingSKMcCullochCEOsteoporotic Fractures in Men (MrOS) Research GroupLoss of hip BMD in older men: the osteoporotic fractures in men (MrOS) studyJ Bone Miner Res200924101728173519419308
   PubMed Web of Science ®Google Scholar
• EnsrudKETaylorBCPaudelMLOsteoporotic Fractures in Men Study GroupSerum 25-hydroxyvitamin D levels and rate of hip bone loss in older menJ Clin Endocrinol Metab20099482773278019454586
   PubMed Web of Science ®Google Scholar
• NielsonCMMarshallLMAdamsALOsteoporotic Fractures in Men Study Research GroupBMI and fracture risk in older men: the osteoporotic fractures in men study (MrOS)J Bone Miner Res201126349650220814955
   PubMed Web of Science ®Google Scholar
• SolimeoSLWeberTJGoldDTOlder men’s explanatory model for osteoporosisGerontologist201151453053921310768
   PubMed Web of Science ®Google Scholar
• SambrookPNFlahiveJHoovenFHPredicting fractures in an international cohort using risk factor algorithms without BMDJ Bone Miner Res201126112770277721887705
   PubMed Web of Science ®Google Scholar
• BoonenSDejaegerEVanderschuerenDOsteoporosis and osteoporotic fracture occurrence and prevention in the elderly: a geriatric perspectiveBest Pract Res Clin Endocrinol Metab200822576578519028356
   PubMed Web of Science ®Google Scholar
• RizzoliRBruyereOCannata-AndiaJBManagement of osteoporosis in the elderlyCurr Med Res Opin200925102373238719650751
   PubMed Web of Science ®Google Scholar
• Prieto-AlhambraDNoguesXJavaidMKAn increased rate of falling leads to a rise in fracture risk in postmenopausal women with self-reported osteoarthritis: a prospective multinational cohort study (GLOW)Ann Rheum Dis201372691191722730372
   PubMed Web of Science ®Google Scholar
• SwitzerJAJaglalSBogochEROvercoming barriers to osteoporosis care in vulnerable elderly patients with hip fracturesJ Orthop Trauma200923645445919550234
   PubMed Web of Science ®Google Scholar
• KamatariMKotoSOzawaNFactors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronateJ Bone Miner Metab200725530230917704995
   PubMed Web of Science ®Google Scholar
• SaleJEGignacMAHawkerGDecision to take osteoporosis medication in patients who have had a fracture and are ‘high’ risk for future fracture: a qualitative studyBMC Musculoskelet Disord2011129221554729
   PubMed Web of Science ®Google Scholar
• HaasumYFastbomJFratiglioniLJohnellKUndertreatment of osteoporosis in persons with dementia? A population-based studyOsteoporos Int20122331061106821499775
   PubMed Web of Science ®Google Scholar
• SchneiderJLFinkHAEwingSKEnsrudKECummingsSRStudy of Osteoporotic Fractures (SOF) Research GroupThe association of Parkinson’s disease with bone mineral density and fracture in older womenOsteoporos Int20081971093109718301855
   PubMed Web of Science ®Google Scholar
• PazianasMCooperCEbetinoFHRussellRGLong-term treatment with bisphosphonates and their safety in postmenopausal osteoporosisTher Clin Risk Manag2010632534320668715
   PubMed Web of Science ®Google Scholar
• StevensonMJonesMLDe NigrisEBrewerNDavisSOakleyJA systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosisHealth Technol Assess2005922116015929857
   PubMed Web of Science ®Google Scholar
• Díez-PérezAOlmosJMNoguésXRisk factors for prediction of inadequate response to antiresorptivesJ Bone Miner Res201227481782422161773
   PubMed Web of Science ®Google Scholar
• CooperCJakobFChinnCFracture incidence and changes in quality of life in women with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)Osteoporos Int200819449350117968611
   PubMed Web of Science ®Google Scholar
• BarbagalloMDominguezLJMaugeriDICARO Study GroupQuality of life in osteoporotic women with inadequate clinical response to antiresorptive drugs: results from the ICARO studyAging Clin Exp Res200719Suppl 3242718180604
   PubMedGoogle Scholar
• iofbonehealth.org [homepage on the Internet]Inadequate Responders Working GroupInternational Osteoporosis Foundation [cited May 24, 2013]. Available from: http://www.iofbonehealth.org/bonehealth/inadequate-responders-working-groupAccessed October 24, 2013
   Google Scholar
• Diez-PerezAAdachiJDAgnusdeiDIOF CSA Inadequate Responders Working GroupTreatment failure in osteoporosisOsteoporos Int201223122769277422836278
   PubMed Web of Science ®Google Scholar
• CutlerDMEverettWThinking outside the pillbox – medication adherence as a priority for health care reformN Engl J Med2010362171553155520375400
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAdherence to Long-Term Therapies: Evidence for ActionGenevaWorld Health Organization2003 Available from: http://www.who.int/chp/knowledge/publications/adherence_report/en/Accessed May 24, 2013
   Google Scholar
• CramerJAGoldDTSilvermanSLLewieckiEMA systematic review of persistence and compliance with bisphosphonates for osteoporosisOsteoporos Int20071881023103117308956
   PubMed Web of Science ®Google Scholar
• SampalisJSAdachiJDRampakakisEVaillancourtJKarellisAKindunduCLong-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidenceJ Bone Miner Res201227120221021976304
   PubMed Web of Science ®Google Scholar
• HadjiPClausVZillerVIntorciaMKostevKSteinleTGRAND: the German retrospective cohort analysis on compliance and persistence and the associated risk of fractures in osteoporotic women treated with oral bisphosphonatesOsteoporos Int201223122323121308365
   PubMed Web of Science ®Google Scholar
• LandfeldtEStrömORobbinsSBorgströmFAdherence to treatment of primary osteoporosis and its association to fractures – the Swedish Adherence Register Analysis (SARA)Osteoporos Int201223243344321286686
   PubMed Web of Science ®Google Scholar
• LekkerkerkerFKanisJAAlsayedNGroup for the Respect of Ethics and Excellence in Science (GREES)Adherence to treatment of osteoporosis: a need for studyOsteoporos Int200718101311131717585359
   PubMed Web of Science ®Google Scholar
• LiLRoddamAGitlinMPersistence with osteoporosis medications among postmenopausal women in the UK General Practice Research DatabaseMenopause2012191334021926926
   PubMed Web of Science ®Google Scholar
• NetelenbosJCGeusensPPYpmaGBuijsSJAdherence and profile of non-persistence in patients treated for osteoporosis – a large-scale, long-term retrospective study in The NetherlandsOsteoporos Int20112251537154620838773
   PubMed Web of Science ®Google Scholar
• HalpernRBeckerLIqbalSUKazisLEMacariosDBadamgaravEThe association of adherence to osteoporosis therapies with fracture, all-cause medical costs, and all-cause hospitalizations: a retrospective claims analysis of female health plan enrollees with osteoporosisJ Manag Care Pharm2011171253921204588
   PubMed Web of Science ®Google Scholar
• LandfeldtELundkvistJStrömOThe societal burden of poor persistence to treatment of osteoporosis in SwedenBone201148238038820850576
   PubMed Web of Science ®Google Scholar
• RossSSamuelsEGairyKIqbalSBadamgaravESirisEA meta-analysis of osteoporotic fracture risk with medication nonadherenceValue Health201114457158121669382
   PubMed Web of Science ®Google Scholar
• CottéFEMercierFDe PouvourvilleGRelationship between compliance and persistence with osteoporosis medications and fracture risk in primary health care in France: a retrospective case-control analysisClin Ther200830122410242219167600
   PubMed Web of Science ®Google Scholar
• PatrickARBrookhartMALosinaEThe complex relation between bisphosphonate adherence and fracture reductionJ Clin Endocrinol Metab20109573251325920444916
   PubMed Web of Science ®Google Scholar
• SirisESHarrisSTRosenCJAdherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databasesMayo Clin Proc20068181013102216901023
   PubMed Web of Science ®Google Scholar
• CenterJRBliucDNguyenNDNguyenTVEismanJAOsteoporosis medication and reduced mortality risk in elderly women and menJ Clin Endocrinol Metab20119641006101421289270
   PubMed Web of Science ®Google Scholar
• HorneRWeinmanJPatients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illnessJ Psychosom Res199947655556710661603
   PubMed Web of Science ®Google Scholar
• HorneRWeinmanJHankinsMThe beliefs about medicines questionnaire: the development and evaluation of a new method for assessing the cognitive representation of medicationPsychol Health1999141124
   Web of Science ®Google Scholar
• SirisESGehlbachSAdachiJDFailure to perceive increased risk of fracture in women 55 years and older: the Global Longitudinal Study of Osteoporosis in Women (GLOW)Osteoporos Int2011221273520358360
   PubMed Web of Science ®Google Scholar
• SolomonDHBrookhartMATsaoPPredictors of very low adherence with medications for osteoporosis: towards development of a clinical prediction ruleOsteoporos Int20112261737174320878392
   PubMed Web of Science ®Google Scholar
• Barrett-ConnorEWadeSWDoTPTreatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™Osteoporos Int201223273374121625886
   PubMed Web of Science ®Google Scholar
• Penning-van BeestFJGoettschWGErkensJAHeringsRMDeterminants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosisClin Ther200628223624216678644
   PubMed Web of Science ®Google Scholar
• CarrAJThompsonPWCooperCFactors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional surveyOsteoporos Int200617111638164416896510
   PubMed Web of Science ®Google Scholar
• SkedrosJGHolyoakJDPittsTCKnowledge and opinions of orthopaedic surgeons concerning medical evaluation and treatment of patients with osteoporotic fractureJ Bone Joint Surg Am2006881182416391245
   PubMed Web of Science ®Google Scholar
• LewieckiEMBabbittAMPiziakVKOzturkZEBoneHGAdherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluationClin Ther200830460562118498910
   PubMed Web of Science ®Google Scholar
• CramerJALynchNOGaudinAFWalkerMCowellWThe effect of dosing frequency on compliance and persistence with bisphosphonate therapy in postmenopausal women: a comparison of studies in the United States, the United Kingdom, and FranceClin Ther200628101686169417157124
   PubMed Web of Science ®Google Scholar
• BartlRGötteSHadjiPHammerschmidtTAdherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatmentDtsch Med Wochenschr20061312212571262 German16755420
   PubMed Web of Science ®Google Scholar
• ReckerRRGallagherRMacCosbePEEffect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of womenMayo Clin Proc200580785686116007889
   PubMed Web of Science ®Google Scholar
• BrankinEWalkerMLynchNAsprayTLisYCowellWThe impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databasesCurr Med Res Opin20062271249125616834823
   PubMed Web of Science ®Google Scholar
• Penning-van BeestFJErkensJAOlsonMHeringsRMDeterminants of non-compliance with bisphosphonates in women with postmenopausal osteoporosisCurr Med Res Opin20082451337134418380910
   PubMed Web of Science ®Google Scholar
• LeeYKNhoJHHaYCKooKHPersistence with intravenous zoledronate in elderly patients with osteoporosisOsteoporos Int20122392329233322179417
   PubMed Web of Science ®Google Scholar
• ZillerVKostevKKyvernitakisIBoeckhoffJHadjiPPersistence and compliance of medications used in the treatment of osteoporosis – analysis using a large scale, representative, longitudinal German databaseInt J Clin Pharmacol Ther201250531532222541835
   PubMed Web of Science ®Google Scholar
• BauerDCBlackDEnsrudKUpper gastrointestinal tract safety profile of alendronate: the fracture intervention trialArch Intern Med2000160451752510695692
   PubMedGoogle Scholar
• LibermanUALong-term safety of bisphosphonate therapy for osteoporosis: a review of the evidenceDrugs Aging200623428929816732688
   PubMed Web of Science ®Google Scholar
• WooCGaoGWadeSHochbergMCGastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US studyCurr Med Res Opin20102641003100920201623
   PubMed Web of Science ®Google Scholar
• ReckerRRLewieckiEMMillerPDReiffelJSafety of bisphosphonates in the treatment of osteoporosisAm J Med2009122Suppl 2S22S3219187809
   PubMed Web of Science ®Google Scholar
• GrimaDTPapaioannouAAiriaPIoannidisGAdachiJDAdverse events, bone mineral density and discontinuation associated with generic alendronate among postmenopausal women previously tolerant of brand alendronate: a retrospective cohort studyBMC Musculoskelet Disord2010116820388226
   PubMed Web of Science ®Google Scholar
• KanisJAReginsterJYKaufmanJMA reappraisal of generic bisphosphonates in osteoporosisOsteoporos Int201223121322121953472
   PubMed Web of Science ®Google Scholar
• NadrashTAPlushnerSLDelateTClinical pharmacists’ role in improving osteoporosis treatment rates among elderly patients with untreated atraumatic fracturesAnn Pharmacother200842333434018303134
   PubMed Web of Science ®Google Scholar
• GiangregorioLDolovichLCranneyAOsteoporosis risk perceptions among patients who have sustained a fragility fracturePatient Educ Couns200974221322018977628
   PubMed Web of Science ®Google Scholar
• BoudouLGerbayBChopinFOllagnierEColletPThomasTManagement of osteoporosis in fracture liaison service associated with long-term adherence to treatmentOsteoporos Int20112272099210621528360
   PubMed Web of Science ®Google Scholar
• Ojeda-BrunoSNaranjoAFrancisco-HernándezFSecondary prevention program for osteoporotic fractures and long-term adherence to bisphosphonatesOsteoporos Int20112261821182820924747
   PubMed Web of Science ®Google Scholar
• NewmanEDMatzkoCKOlenginskiTPGlucocorticoid-Induced Osteoporosis Program (GIOP): a novel, comprehensive, and highly successful care program with improved outcomes at 1 yearOsteoporos Int20061791428143416865312
   PubMed Web of Science ®Google Scholar
• CottéFEDe PouvourvilleGCost of non-persistence with oral bisphosphonates in post-menopausal osteoporosis treatment in FranceBMC Health Serv Res20111115121702989
   PubMed Web of Science ®Google Scholar
• PatrickARSchousboeJTLosinaESolomonDHThe economics of improving medication adherence in osteoporosis: validation and application of a simulation modelJ Clin Endocrinol Metab20119692762277021733991
   PubMed Web of Science ®Google Scholar